Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

BET inhibitor exhibits activity in myelofibrosis

Publish date:: January 14, 2020

Key clinical point: The BET inhibitor CPI-0610, given alone or in combination with ruxolitinib, has demonstrated activity in a phase 2 trial of patients with relapsed/refractory myelofibrosis.

Major finding: Of 9 evaluable patients who received CPI-0610 monotherapy, 4 had a 50% or greater improvement in total symptom score, as did 12 of 27 evaluable patients who received CPI-0610 and ruxolitinib.

Study details: A phase 2 trial of 90 patients, 36 who received monotherapy and 54 who received the combination.

Disclosures: The trial is funded by Constellation Pharmaceuticals in collaboration with the Leukemia & Lymphoma Society. Dr. Mascarenhas reported relationships with Incyte, Janssen, CTI Biopharma, Novartis, Roche, Merck, Celgene, Promedior, Merus, and PharmaEssentia.

Citation:

Mascarenhas J et al. ASH 2019, Abstract 670.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Cythemias

BET inhibitor exhibits activity in myelofibrosis,

Navitoclax may overcome ruxolitinib resistance in MF,

Back to the drawing board for MPN combo,